

## Does Tirzepatide Affect Clinical Outcomes in Individuals With OSA and Obesity?

### STUDY DESIGN

- Retrospective cohort trial using the TriNetX Global Collaborate Network
- Included patients with obesity and OSA
- Tirzepatide compared with lifestyle interventions
- **Primary outcome:** all-cause mortality
- **Secondary outcomes:** major adverse cardiovascular events, major adverse kidney events

### RESULTS

**TIRZEPATIDE** was associated with a lower risk of:



**All-Cause Mortality**

HR, 0.443 (95% CI, 0.336-0.583)



**Major Adverse Cardiovascular Events**

HR, 0.731 (95% CI, 0.622-0.859)



**Major Adverse Kidney Events**

HR, 0.427 (95% CI, 0.343-0.530)

**42,300 Patients**

**Tirzepatide Group: 21,150**

**Lifestyle Intervention Group: 21,150**



The findings of this study suggest that tirzepatide could be associated with reduced mortality, cardiovascular events, and kidney-related complications in patients with OSA and obesity.